ENVB — Enveric Biosciences, Inc.
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2017-11-17.
Performance
Technicals
Others in Healthcare
Measured signals that fired on ENVB
| date | signal | measured base rate |
|---|---|---|
| 2026-06-08 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
| 2026-06-04 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-30 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-04-20 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-04-20 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-03-05 | Equal lows taken out structure | -0.64% over 21 days · t = -4.75 · n = 55,661 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-01 | Schabacker Marcus Director | Grant or award | 18.5K | 0.00 | 0 |
| 2026-06-01 | WEBB MICHAEL D Director | Grant or award | 18.5K | 0.00 | 0 |
| 2026-06-01 | DeWitt Sheila Director | Grant or award | 18.5K | 0.00 | 0 |
| 2026-06-01 | Coveney Kevin Michael Chief Financial Officer | Grant or award | 133.3K | 0.00 | 0 |
| 2026-06-01 | Kegler George A. Director | Grant or award | 18.5K | 0.00 | 0 |
| 2026-06-01 | Tucker Joseph Edward Chief Executive Officer | Grant or award | 201.1K | 0.00 | 0 |
| 2026-06-01 | Facchini Peter J. Chief Innovation Officer | Grant or award | 25.0K | 0.00 | 0 |
| 2026-06-01 | PASQUALONE FRANK Director | Grant or award | 18.5K | 0.00 | 0 |
| 2025-12-23 | DeWitt Sheila Director | Grant or award | 7.6K | 0.00 | 0 |
| 2025-12-23 | Schabacker Marcus Director | Grant or award | 7.6K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| GEODE CAPITAL MANAGEMENT, LLC | 62.4K | 32.1K |
| AdvisorShares Investments LLC | 32.9K | 17.0K |
| UBS Group AG | 7.0K | 3.6K |
| Tower Research Capital LLC (TRC) | 2.1K | 1.1K |
| JONES FINANCIAL COMPANIES LLLP | 1.9K | 1.0K |
| SBI Securities Co., Ltd. | 161 | 83 |
| BlackRock, Inc. | 99 | 51 |
| GROUP ONE TRADING LLC | 2 | 1 |
| NATIONAL BANK OF CANADA /FI/ | 2 | 1 |
| DANSKE BANK A/S | 2 | 1 |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Latest SEC filings
| form | filed | period | |
|---|---|---|---|
| 10-Q | 2026-08-14 | 2026-06-30 | on EDGAR ↗ |
| 8-K | 2026-08-14 | 2026-08-14 | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G | 2026-08-14 | — | on EDGAR ↗ |
| SCHEDULE 13G/A | 2026-08-13 | — | on EDGAR ↗ |
| 8-K | 2026-06-09 | 2026-06-09 | on EDGAR ↗ |
| 424B5 | 2026-06-09 | — | on EDGAR ↗ |
| 8-K | 2026-06-09 | 2026-06-08 | on EDGAR ↗ |
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Enveric Biosciences GAAP EPS of -$0.76 · 2026-08-17
- Enveric Biosciences, Inc. (ENVB) filed form 10-Q · 2026-08-14 · SEC EDGAR
- Enveric Biosciences, Inc. (ENVB) filed form 8-K · 2026-08-14 · SEC EDGAR
- Enveric Biosciences, Inc. (ENVB) filed form SCHEDULE 13G/A · 2026-08-14 · SEC EDGAR
- Enveric Biosciences, Inc. (ENVB) filed form SCHEDULE 13G · 2026-08-14 · SEC EDGAR
- Enveric Biosciences, Inc. (ENVB) filed form SCHEDULE 13G/A · 2026-08-13 · SEC EDGAR
Ask the AI about ENVB
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →